The addition of DPP-4 inhibitor and SGLT-2 inhibitor fixed-dose combination therapy may be considered in asymptomatic T2DM patients who are uncontrolled on metformin with or without a second-line agent and HbA1c ≥9%. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.